InMode Ltd. (NASDAQ:INMD) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,084,241 shares of the healthcare company's stock after purchasing an additional 45,638 shares during the period. JPMorgan Chase & Co. owned about 1.56% of InMode worth $18,107,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of InMode by 54.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company's stock valued at $2,127,000 after acquiring an additional 44,058 shares in the last quarter. State Street Corp raised its holdings in shares of InMode by 3.7% in the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company's stock valued at $34,657,000 after purchasing an additional 73,183 shares in the last quarter. National Bank of Canada FI lifted its position in shares of InMode by 6.2% in the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company's stock worth $169,000 after purchasing an additional 579 shares during the period. XTX Topco Ltd bought a new position in shares of InMode during the third quarter valued at approximately $286,000. Finally, Orion Portfolio Solutions LLC purchased a new position in InMode during the third quarter valued at approximately $194,000. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group dropped their price objective on InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research report on Monday. Needham & Company LLC restated a "hold" rating on shares of InMode in a research note on Wednesday, April 9th. Finally, Barclays lifted their price objective on shares of InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, InMode has a consensus rating of "Hold" and a consensus target price of $21.25.

InMode Trading Down 0.3 %

Shares of InMode stock traded down $0.05 during trading hours on Thursday, reaching $14.87. The stock had a trading volume of 153,280 shares, compared to its average volume of 1,175,713. InMode Ltd. has a twelve month low of $13.68 and a twelve month high of $19.85. The firm has a market capitalization of $1.03 billion, a PE ratio of 6.34 and a beta of 1.96. The stock's 50 day moving average is $17.83 and its 200 day moving average is $17.62.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.